CEO, SR One
Dr. Simeon J. George
Dr. Simeon George has served on our Board of Directors since April 2015. Dr. George joined SR One in 2007 and is CEO of the fund. He earned his M.D. and M.B.A. from the University of Pennsylvania School of Medicine / Wharton and B.A. from Johns Hopkins University. Previously, he worked in management consulting (Bain & Co.) and investment banking (Goldman Sachs). Simeon led SR One’s investments in several deals including CRISPR Therapeutics (CRSP), Principia Biopharma (PRNB, recently acquired by Sanofi for $3.7bn), Turning Point Therapeutics (TPTX), Progyny (PGNY), and Nkarta Therapeutics (NKTX), which he co-founded.
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.